Androgen Deprivation Therapy News and Research

RSS

Insights into testosterone recovery after androgen deprivation therapy for prostate cancer

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.

26 Sep 2024

Major funding boost aims to advance research on bone metastasis in breast and prostate cancers

Breast Cancer Now and Prostate Cancer Research have joined forces to fund up to £600,000 of new research to tackle the spread of both cancers to the bones, known as bone metastasis.

6 Sep 2024

Study explores link between prostate cancer treatment and Alzheimer’s disease

Researchers at the Medical College of Georgia at Augusta University are searching for a better way to understand why many men with prostate cancer end up with Alzheimer's disease, and whether it's the standard hormone therapy treatment or an overactive immune response that actually contributes to the problem.

29 Aug 2024

Olaparib effective against BRCA2-mutated prostate cancer

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.

23 Aug 2024

New nanoparticle-based immunotherapy delays hormone therapy resistance in prostate cancer

A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer.

5 Aug 2024

Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer

A recent European Urology Oncology study assessed the mortality risks, based on the Gleason score and clinical parameters, in patients with prostate cancer.

11 Jul 2024

Pharmacogenomics: A pathway to personalized treatment in prostate cancer

Prostate cancer (PC) stands as the second leading cause of death among American men, with about 1 in 8 men diagnosed during their lifetime.

2 Jul 2024

Integrating PGx testing for personalized prostate cancer treatment

Prostate cancer (PC) is a significant health concern, being the second leading cause of death among American men.

31 May 2024

Long-term prostate cancer treatment study informs decisions for diverse groups

A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population.

23 Jan 2024

Rutgers researchers devise strategy to boost prostate cancer treatment efficacy

Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer.

22 Jan 2024

New study unlocks hope for immunotherapy in metastatic prostate cancer

Immunotherapy has been disappointing as a prostate cancer treatment, but a new Columbia study suggests that the powerful treatments have potential when the disease starts to spread.

12 Dec 2023

Study finds racial disparity in the utilization of crucial prostate cancer therapy

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups – including white or Latino men – despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.

1 Dec 2023

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis.

1 Nov 2023

Scientists identify two promising new treatment options for men with recurrent prostate cancer

Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with recurrent prostate cancer-; both of which helped patients live longer without their disease progressing than the current standard treatment.

18 Oct 2023

New treatment approach effectively treats the most aggressive forms of prostate cancer

Researchers at the University of Chicago Medicine Comprehensive Cancer Center established "proof-of-concept" for a new treatment approach that was able to effectively treat the most aggressive forms of prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.

19 Sep 2023

Study challenges the use of biochemical recurrence as prostate cancer predictor

A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival.

28 Aug 2023

Androgen deprivation therapy increases the risk of depression, dementia, Alzheimer’s disease, and Parkinson’s disease

The association between Androgen Deprivation Therapy (ADT) and the risk of dementia.

16 Aug 2023

Copy number profiling provides insight as to why prostate cancer may become lethal

Researchers performed genome-wide copy number profiling of the androgen receptor (AR) on metastases from deceased prostate cancer patients.

16 Aug 2023

Researchers validate first-ever AI biomarker for ADT benefit in prostate cancer

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.

30 Jun 2023

Study investigates whether metformin mitigates androgen deprivation therapy-related metabolic syndrome

A new research paper was published in Oncotarget's Volume 14 on June 19, 2023, entitled, "Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer."

21 Jun 2023